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The role of hematopoietic cell transplantation (HCT) in the therapy of Hodgkin lymphoma (HL) in pediatric
and adult patients is reviewed and critically evaluated in this systematic evidence-based review. Speciﬁc
criteria were used for searching the published literature and for grading the quality and strength of the
evidence and the strength of the treatment recommendations. Treatment recommendations based on the
evidence are included and were reached unanimously by a panel of HL experts. Both autologous and allo-
geneic HCT offer a survival beneﬁt in selected patients with advanced or relapsed HL and are currently part of
standard clinical care. Relapse remains a signiﬁcant cause of failure after both transplant approaches, and
strategies to decrease the risk of relapse remain an important area of investigation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION literature for the use of blood and marrow transplantation in
In 1999 the American Society for Blood and Marrow
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ty for Blood and Marrow Transplantation.the therapy of selected diseases. Eight previous reviews and
3 updates have been published in Biology of Blood and
Marrow Transplantation for these diseases: diffuse large B cell
non-Hodgkin lymphoma [1,2], multiple myeloma [3], pedi-
atric acute lymphocytic leukemia [4,5], adult acute lym-
phocytic leukemia [6,7], pediatric acute myeloid leukemia
[8], adult acute myeloid leukemia [9], myelodysplastic syn-
drome [10], and follicular lymphoma [11]. The goals of this
review are to assemble and critically evaluate all evidence
regarding the role of hematopoietic cell transplantation
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(HL), make treatment recommendations based on the avail-
able evidence, and identify areas of needed research.EXPERT PANEL AND GRADING SYSTEM
Experts in the treatment of HL were invited to join the
independent expert panel that examined the literature and
provided subsequent treatment recommendations based on
the available evidence. Members of the expert panel ﬁrst
reviewed and agreed on a list of topics to be included in the
review. Articles were then organized into subtopics by 2
authors (M.-A.P. and I.C.), and reviewers were provided with
a list of studies speciﬁc to the subtopic they were reviewing
as well as a master list of all studies.
A standardized grading system that includes grading the
levels of evidence was used to grade the studies included in
this review and the treatment recommendations [12], as
recommended by the ASBMT Steering Committee for
evidence-based reviews [13] (Supplemental Tables 1 and 2).
Studies were also evaluated based on study design, sample
size, patient selection criteria, duration of follow-up, and
treatment plan. Articles in each subtopic were reviewed and
graded by 2 to 3 experts, who then submitted treatment
recommendations. When differences were noted in the
grading system, the lead author (M.-A.P.) discussed these
with the reviewers for that speciﬁc topic and consensus was
reached for the ﬁnal grading and recommendation. This
iterative process concluded when ﬁnal versions of the
treatment recommendation tables were approved by all
panelists.
After the ﬁnal draft of the review was approved by the
disease-speciﬁc expert panel, it underwent peer review, ﬁrst
by the ASBMT Committee on Practice Guidelines and then by
the ASBMT Executive Committee before submission to the
journal. Any changes requested during the peer-review
process were reviewed and approved by all disease-speciﬁc
expert panelists.LITERATURE SEARCH METHODOLOGY
The literature search methodology was adapted from the search
methodology used for the diffuse large B cell non-HL evidence-based review
update published in 2011 [2], with the following modiﬁcation: articles that
included fewer than 20 HL (rather than 25 as for diffuse large B cell non-HL)
cases were excluded because of the lower incidence of the disease. PubMed
was searched in July 2012, using the search terms “Hodgkin Lymphoma”
AND “transplant” limited to “human trials,” “English language,” and a
publication date of January 1, 2001 or later. The search terms were
(“Hodgkin disease”[MeSH Terms] OR (“Hodgkin”[All Fields] AND “dis-
ease”[All Fields]) OR “Hodgkin disease”[All Fields] OR (“Hodgkin”[All Fields]
AND “lymphoma”[All Fields]) OR “Hodgkin lymphoma”[All Fields]) AND
(“transplants”[MeSH Terms] OR “transplants”[All Fields] OR “transplant”[All
Fields] OR “transplantation”[MeSH Terms] OR “transplantation”[All Fields])
AND ((“2001/01/01”[PDAT]: “3000/12/31”[PDAT]) AND “humans”[MeSH
Terms] AND English[lang]). Articles published before January 2001, included
fewer than 20 HL patients, or were not peer reviewed were excluded. Also
excluded were editorials, letters to the editor, phase I (dose escalation or
dose ﬁnding) studies, reviews, consensus conference papers, practice
guidelines, and laboratory studies with no clinical correlates.
The initial search resulted in the identiﬁcation of 2004 papers. Of these,
166 were selected for the evidence-based review. Two updated searches
were performed in April 2013 to include articles published in 2012 (172
articles identiﬁed, 14 articles previously not identiﬁed selected) and in
September 2014 to include articles published in 2014 (187 articles identiﬁed,
20 articles previously not identiﬁed selected). A total of 200 articles were
included in the review. All articles were brieﬂy reviewed and classiﬁed by 2
authors (M.-A.P. and I.C.), who also retrieved basic information on the
studies, including study design and number of patients. Finally, additional
important studies presented in 2014 have been included.SUMMARY RECOMMENDATIONS
This section highlights summary recommendations for
both autologous stem cell transplant (ASCT, Table 1) and
allogeneic HCT (allo-HCT, Table 2) for patients with HL that
are based on higher level evidence.What Are the Indications for ASCT in HL?
Table 3 outlines the recommendations for the use of ASCT
versus nontransplantation therapy.
Role of up-front ASCT
Results from randomized studies support that ASCT
should not be performed as consolidation even in patients
with high-risk or advanced disease [14-16]. Long-term
follow-up of a randomized study of 163 patients with unfa-
vorable HL showed similar 10-year overall survival (OS) of
85% (95% conﬁdence interval [CI], 78% to 90%) and 84% (95%
CI, 77% to 89%) for patients who underwent high-dose
therapy and ASCT or conventional chemotherapy, respec-
tively [14,16]. Similar results were noted in a randomized
study comparing early versus late intensiﬁcation [15].
ASCT for relapse or primary induction failure
HL is one of the most common indications for ASCT [117].
The expert panel recommends that persistent or relapsed
disease be conﬁrmed by biopsy. In contrast to up-front ASCT,
outcomes in patients who have relapsed have shown a
beneﬁt of ASCT over conventional therapy [17-21,24-26,29-
32]. Schmitz et al. [17] randomized 161 patients with
relapsed HL to ASCT versus chemotherapy, with 144 patients
with chemosensitive disease proceeding with the planned
treatment. Although no signiﬁcant difference in OS was
found between the 2 groups, freedom from treatment failure
at 3 years was signiﬁcantly improved among patients who
underwent ASCT (55%) compared with those treated with
chemotherapy (34%; P ¼ .019). Several retrospective studies
that reported favorable outcomes with ASCT have combined
patients with relapsed disease or primary induction failure in
the analysis. In general, progression-free survival (PFS)
ranged from 50% to 60% and OS from 50% to 80% for patients
who had relapsed [18-21,24-26,29-32,39,69,117]. Patients
with primary induction failure also appear to beneﬁt from
ASCT, with reported PFS rates of 40% to 45% and OS rates of
30% to 70% [17-28,69]. This area, however, remains contro-
versial because it is supported only by retrospective data.
A recent Cochrane review on the role of ASCT in HL
concluded that although ASCT as salvage therapy improves
event-free survival (EFS) and PFS compared with nontrans-
plant approaches, the beneﬁt for OS showed a positive trend
in favor of ASCT but did not reach statistical signiﬁcance [33].
Although ASCT is the most commonly recommended salvage
therapy, exceptions can be made for patients with localized
late relapses who may beneﬁt from salvage chemotherapy or
involved ﬁeld radiation therapy (IFRT) only when the lesion
is amenable to this approach [30,31,34]. A review of existing
pediatric data similarly concluded that salvage chemo-
therapy and radiation may provide similar outcomes to ASCT
for subsets of pediatric HL patients [118].Additional Considerations for the Use of ASCT in HL:
Salvage, Conditioning, IFRT, and Special Populations
Additional considerations for ASCT use are displayed in
Table 4.
Table 1
Summary of Treatment Recommendations for ASCT for HL
Recommendation Grade of
Recommendation
Highest Level
of Evidence
References
ASCT should not be offered as ﬁrst-line therapy for advanced disease A 1þ [14-16]
ASCT should be offered as ﬁrst-line therapy for patients who fail to achieve CR B 2þþ [17-28]
ASCT should be offered as salvage therapy over nontransplantation (except localized disease,
where IFRT may be considered, or patients with low-stage disease and late relapse, where
chemotherapy may be considered)
A 1þ [17-21,24-26,29-33]
ASCT should be offered to pediatric patients with primary refractory disease or high-risk
relapse who respond to salvage therapy
B 2þþ [30,34-39]
Several salvage chemotherapy regimens may be considered before ASCT in adult patients B 2þþ [40-51]
Several salvage chemotherapy regimens may be considered before ASCT in pediatric patients B 2þþ [52-56]
BEAM or CBV are the most common conditioning regimens for ASCT in standard-risk patients B 2þþ [20,21,39,51,57-71]
IFRT should be considered in patients with bulky disease not previously irradiated C 2þ [51,65,72-74]
Tandem ASCT is not routinely recommended in standard-risk patients C 2þ [75-79]
Maintenance therapy with brentuximab vedotin post-ASCT is recommended in
high-risk patients*
A 1þ [80]
Chemosensitive disease and negative functional imaging are associated with improved
outcome
B 2þþ [51,69,81-88]
* High-risk patients were deﬁned in the AETHERA trial as having 1 of the following: refractory to frontline therapy, relapse < 12 months after frontline
therapy, or relapse  12 months after frontline therapy with extranodal disease [80].
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A number of studies have looked at different salvage and
conditioning regimens. Platinum-based regimens with
nonecross-resistant drugs are the preferred regimens for
salvage and stem cell mobilization in the United States
(Supplemental Table 3a). One of the most commonly used
regimens is ICE (ifosfamide, carboplatin, and etoposide)
[40,51], although alternative salvage regimens such as ESHAP
(etoposide, methylprednisolone, high-dose cytarabine, and
cisplatin) or gemcitabine-containing regimens such as GDP
(gemcitabine, dexamethasone, cisplatin) or IGEV (ifosfamide,
gemcitabine, etoposide, vinorelbine) are considered accept-
able alternatives [41-50,65,119]. In the study by Moskowitz
et al. [40], the response rate to 2 cycles of ICE was 88% in 65
patients with HL (22 with primary refractory and 43 with
relapsed HL). The OS and EFS rates for patients who under-
went transplantationwere 83% and 68%, respectively. Similar
results have been reported with the other regimens, with
overall response rates (ORRs) ranging from 62% to 88%, OS
rates from 52% to 90%, and EFS rates from 36% to 70%. One
study that randomized patients to further intensiﬁcation of
salvage therapy before ASCT did not show a survival beneﬁt
and higher toxicity [121]. In a more recent study, the use of
sequential nonecross-resistant regimens, based on restaging
with 2-deoxy-2-[ﬂuorine-18]ﬂuoro-D-glucose (18F-FDG)
positron emission tomography (PET) scan after 2 cycles of
ICE, was examined [51]. Patients with a negative scan pro-
ceeded to transplantation, whereas those who still had a
positive scan received 4 biweekly doses of GVD (gemcitabine,
vinorelbine, and liposomal doxorubicin) and were subse-
quently transplanted if they had a negative scan. The EFSTable 2
Summary of Treatment Recommendations for Allo-HCT for HL
Recommendation Grad
Recom
Allo-HCT should be used instead of conventional therapy for relapse
after ASCT
B
RIC is the recommended regimen intensity B
All donor sources can be considered A
DLI can be given for relapse or progressive disease
(limited data for mixed donor chimerism)
B
There are limited data for tandem ASCT/Allo-HCT D
Allo-HCT is preferred over ASCT as second HCT (except in late relapse) Crates was >80% in patient transplanted with negative FDG-
PET after 1 or 2 salvage programs versus 28.6% for patients
with a positive scan (P < .001).
With the approval of the antibody drug conjugate tar-
geting CD30 brentuximab vedotin in patients who relapse
after an ASCT or fail to achieve a remission after second-line
therapy [122], its use is being investigated in the salvage
setting before ASCT, either as a single agent (NCT01508312,
NCT01393717) or in combination with bendamustine
(NCT01874054). In a study by Moskowitz et al. [123], 45
patients with relapsed/refractory HL who failed 1 prior
regimen received weekly brentuximab vedotin for 2 cycles
followed by a PET scan. Twenty-seven percent achieved a PET
complete remission (CR) and proceeded directly to high-
dose therapy/ASCT; 32 remaining patients with persistent
abnormalities on PET received 2 cycles of augmented ICE, 22
of whom normalized their PET. After a median follow-up of
23 months, 80% of patients were event-free. Similarly, in a
study by Chen et al. [124], 37 patients with relapsed/re-
fractory HL who failed induction chemotherapy received
brentuximab vedotin once every 3weeks for amaximum of 4
cycles. Thirty-six percent achieved a PET CR, with an ORR of
69%. Patients not in CR were allowed to receive additional
salvage chemotherapy before transplantation. Finally, the
combination of bendamustine and brentuximab vedotin is
also being studied in relapsed patients [125]. Preliminary
results have shown a CR rate of 82% and ORR of 94% in 45
patients treated with this combination.
It should be noted that the latter 2 studies have only been
presented in abstract form, and the reader is referred to the
ﬁnal publications when they are available. Fore of
mendation
Highest Level
of Evidence
References
2þþ [89-94]
2þþ [91,95-110]
1þ [96,100-102,104,105,111-113]
2þþ [89,91,95-98,102,104,105,109,114,115]
4 [91]
2þ [90,116]
Table 3
ASCT versus Nontransplantation Therapy
Recommendation Grade of
Recommendation
Highest Level
of Evidence
References
Should ASCT be offered as ﬁrst-line therapy for advanced disease? No A 1þ [14-16]
Should ASCT be offered as ﬁrst-line therapy for patients
who fail to achieve a CR?
Yes B 2þþ [17-28,69]
Should ASCT or nontransplantation be offered as salvage therapy? ASCT A 1þ [17-21,24-26,29-33,39]
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referred to recent guidelines on this topic published by
ASBMT [126,127].
Salvage regimens for pediatric and young adult patients
A broad array of salvage regimens have been tested in
clinical trials for pediatric and young adult patients
(Supplemental Table 3b). Although these regimens differ
signiﬁcantly in intensity, the observed ORRs overlap. For this
reason, salvage therapy for pediatric patientswith relapsed or
refractoryHLnotenrolled ona clinical trialmaybe selectedby
considering risk for acute and chronic toxicity. The combi-
nation of gemcitabine with vinorelbine is an example of a
salvage regimen that avoids additional alkylating agents or
etoposide yet produces high response rates and successful
stemcell collection among pediatric and young adult patients
with relapsed or refractory HL [50,54]. More intensive regi-
mens (eg, ifosfamide with vinorelbine, ICE, or high-dose
methotrexate, ifosfamide, etoposide, dexamethasone) can
be reserved for those patients who do not have a negative
FDG-PETscan after the initial salvage regimen [55]. Collection
of stem cells after priming with an etoposide-containing
regimen may increase the risk of secondary malignancies
post-transplantation [128], for example, and should be
approached with caution. Once achieving a CR deﬁned by
negative functional imaging (FDG-PET), all pediatric and
young adult patients with primary refractory disease and
most with relapsed HL should proceed to high-dose chemo-
therapy with ASCT. Conventional chemotherapy with or
without radiation therapy can be considered for those with
low-risk relapse, deﬁned by initial stage other than IIIB or IVB,
time to relapse greater than 12 months, and absence of
extranodal disease or B symptoms at relapse.Table 4
Additional Considerations for ASCT
Recommendation
What are common regimens of salvage therapy
before ASCT in adult patients?
ICE, ESHAP, or GDP
What are common regimens of salvage therapy
before ASCT in pediatric patients?
GV, IV
What is the recommended conditioning regimen for ASCT? BEAM, CBV, Bu/Cy
or TLI/chemotherap
Is there a role for tandem ASCT? Not in standard-ris
What is the role of IFRT and when should it be performed? Recommended in b
previously not irra
in most centers
Should maintenance therapy be given after ASCT? Yesy
What is the role of comorbidities in outcomes? Paucity of data
Should ASCT be offered to pediatric patients? Yes
GV indicates gemcitabine, vinorelbine; IV, ifosfamide, vinorelbine; Et, etoposide; T
* More recent studies have incorporated brentuximab vedotin in the salvage se
y Maintenance with brentuximab vedotin is recommended in high-risk patient
frontline therapy, relapse < 12 months after frontline therapy, or relapse  12 moConditioning regimens
A number of conditioning regimens are routinely used
for HL (Supplemental Table 4), including BEAM (BCNU, eto-
poside, cytarabine, melphalan), CBV (cyclophosphamide,
carmustine [BCNU], etoposide), Bu/Cy (busulfan, cyclophos-
phamide)  etoposide, Bu/Mel (busulfan, melphalan), or
total lymphoid irradiation/chemotherapy [20,21,39,51,57-
63,65-67,69-71]. For primary refractory HL, some authors
consider radiation-based therapy (eg, total lymphoid irradi-
ation) a preferred approach, although there are no random-
ized data in this regard. Although BEAM is one of the most
commonly used regimens, there are a number of different
dosing variations. In general, the following intravenous
dosing is suggested: BCNU 300 mg/m2, etoposide 800 to
1200mg/m2, cytarabine 1600mg/m2, melphalan 140mg/m2.
Some studies have suggested that more intense regimens
incorporating busulfan, melphalan, and either gemcitabine
or thiotepa may provide an advantage in EFS and OS over
BEAM, despite increased toxicity [69,70]. This may be
particularly the case in poor-risk patients, and further studies
are warranted to address this question. It should be noted,
however, that neither study included patients above the age
of 65, and caution is recommended in using more intense
regimens in older patients in the absence of data.
Finally, a recent analysis by the Center for International
Blood and Marrow Transplant Research (CIBMTR) that
included 1012 patients with HL reported that CBV (with
median BCNU dose of 450 mg/m2; hazard ratio [HR]1.54),
CBV (with median BCNU dose of 300 mg/m2; HR1.53), BuCy
(HR1.77), and total body irradiation (HR 3.39) were associ-
ated with higher mortality compared with BEAM (P < .001)
[71]. Overall, reported treatment-related mortality (TRM) for
ASCT ranges from 0 to 19% in some older series. OS and EFSGrade of
Recommendation
Highest Level
of Evidence
References
* B 2þþ [40-51,119]
B 2þþ [52-56]
(Et), Bu/Mel,
y
B 2þþ [20,21,39,51,57-71]
k patients C 2þ [75-79]
ulky disease
diated, post-ASCT
C 2þ [51,65,72-74]
A 1þ [80]
d d [120]
B 2þþ [30,34-39]
LI, total lymphoid irradiation.
tting (see text for details).
s, deﬁned in the AETHERA trial as having 1 of the following: refractory to
nths after frontline therapy with extranodal disease [80].
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There is a risk of secondary malignancies, particularly mye-
lodysplastic syndrome and treatment-related acute myeloid
leukemia, which has been observed in up to 5% of patients.
Tandem ASCT
Tandem ASCT for HL has been evaluated in a small
number of studies [75-78]. The Groupe d’Étude des Lym-
phomes de l’Adulte/Société Française de Greffe de Moelle
study group performed a prospective multicenter trial to
evaluate risk-adapted salvage therapy with single or tandem
ASCT in 245 HL patients [78]. Ninety-two intermediate-risk
patients (97%) received single ASCT, whereas 105 poor-risk
patients (70%) received tandem ASCT. The 5-year OS esti-
mates were 85% and 57% for the intermediate-risk and poor-
risk group, respectively. In the study by Fung et al. [76], 46
patients with primary progressive or recurrent HL with poor
prognostic factors underwent tandem ASCT. Conditioning
consisted of high-dose melphalan for the ﬁrst transplant and
total body irradiation or BCNU in combination with etopo-
side and cyclophosphamide for the second transplant. Five-
year estimates of OS and PFS were 54% and 49%, respec-
tively. The Southwest Oncology Group recently presented
results of a follow-up phase II study of tandem ASCT in pa-
tients with HL using the same approach (NCT00233987) [79].
Of 92 eligible patients, 89 were treated and 82 completed
both cycles of ASCT, without any TRM.With amedian follow-
up of 5.4 years (range, 2 to 7.6 years), the 2-year PFS rate was
63% (95% CI, 52% to 72%) and 2-year OS rate was 91% (95% CI,
83% to 95%). The high OS is likely due to salvage options for
patients who progress after ASCT, including brentuximab
vedotin and allo-HCT. This study also was only presented in
abstract form at the time of publication. Given the current
data, the panel does not recommend routine use of tandem
ASCT for patients with HL, although further studies may be
warranted in high-risk patients.
Role of IFRT
Patients with HL undergoing ASCT remain at risk for
relapse, particularly in areas of bulky disease. As a result,
investigators have studied the potential role of IFRT to
decrease the risk of relapse [39,51,65,72-74]. In a study by
Kahn et al. [74], 46 HL patients treated with IFRT within 2
months of ASCT were matched to 46 HL patients who did not
receive IFRT. The use of IFRT signiﬁcantly improved disease-
free survival (P¼ .032), but not OS, when stratiﬁed by disease
bulk. Most centers have adopted the use of peritransplant
IFRT in patients with bulky disease who have not previously
been irradiated. There are no speciﬁc data regarding the
timing of IFRT, either before or after ASCT. In general, most
centers perform IFRT after ASCT. The potential beneﬁts of
IFRT need to be weighed against the risk of pulmonary
toxicity [129].
Post-ASCT maintenance
The use of brentuximab vedotin for post-transplant
maintenance was investigated in a randomized phase III
study that included 327 patients [80]. Patients were enrolled
on the study if theymet criteria for high-risk disease, deﬁned
as having one of the following: refractory to frontline ther-
apy, relapse< 12months after frontline therapy, or relapse
12 months after frontline therapy with extranodal disease.
Patients were required to have obtained a CR, partial
remission (PR), or stable disease to salvage therapy before
ASCT. Thirty to 45 days after transplant, patients wererandomized to receive either brentuximab vedotin or pla-
cebo for up to 1 year. With a median follow-up of 2 years, PFS
was 65% in the treatment arm versus 45% in the placebo
group (hazard ratio, .50; 95% CI, .36 to .70]. Two-year OS was
the same in both arms at 88%, but crossover was allowed in
the placebo arm. Based on the phase III data, we recommend
the use of post-ASCTmaintenancewith brentuximab vedotin
in high-risk patients. The histone deacetylase inhibitor
panobinostat was also under evaluation for post-ASCT
maintenance therapy in a phase III trial (NCT01034163),
based on encouraging phase II data [130], but the study
closed due to slow accrual.
Pediatric ASCT studies
Although there are fewer studies in pediatric patients
(reviewed in [118]), the panel recommends that pediatric
patients also be considered for ASCT based on the data
available and by extrapolation of the adult data [35-39].
These results should be balanced with other studies sug-
gesting similar outcomes with salvage chemotherapy
compared with ASCT in pediatric patients, particularly those
with late relapse (>12 months) [30,34]. The CIBMTR Lym-
phoma Working Committee has approved a study looking at
outcomes of ASCT in children and young adults with HL.
ASCT in older patients and patients with comorbidities
Finally, there are a paucity of data on older patients and
patients with comorbidities, and the panel recommends this
as an area that warrants ongoing research [120,131]. For
recommendations on chemotherapy dosing in obese patients
or patients with renal insufﬁciency, readers are referred to
recent reviews or ASBMT guidelines on these topics
[132,133].
Prognostic Factors for ASCT
Prognostic factors may provide a useful tool to better
stratify patients and use risk-adapted therapy to improve
outcomes (Table 5). Studies have examined prognostic fac-
tors both at time of relapse and before ASCT. It is important
to note that none of the presumed prognostic factors has
been studied in a prospective manner. In the studies re-
ported, we have included risk factors that were associated
with inferior outcome in at least 2 studies. The
following adverse factors were identiﬁed as useful at time
of relapse: anemia (hemoglobin < 10 g/dL), stage (III/IV),
remission duration < 12 months, B symptoms, extranodal
sites of disease, and bulky disease at diagnosis [20-
22,24,25,31,40,41,59,61,62,64,81,134-142]. Short remission
duration is the factor most consistent across different series.
The CIBMTR proposed a prognostic model for PFS after ASCT
in patients with HL [88]. Four adverse factors at the time of
ASCT were identiﬁed in a multivariate analysis: Karnofsky
performance scale score < 90, chemoresistant disease at
ASCT, 3 chemotherapy regimens, and extranodal sites of
disease at ASCT. The ﬁrst 2 factors were assigned 1 point and
the latter 2 factors assigned 2 points. The 4-year PFS in low
(score ¼ 0, n ¼ 176), intermediate (score ¼ 1 to 3, n ¼ 261),
and high (score ¼ 4 to 6, n ¼ 283) groups was 71% (95% CI,
63% to 78%), 60% (95% CI, 53% to 66%), and 41% (95% CI, 36%
to 49%), respectively.
Role of chemosensitive disease
A number of retrospective series have demonstrated that
chemosensitive disease at the time of ASCT, deﬁned as hav-
ing achieved at least PR, is a signiﬁcant prognostic factor for
Table 5
Prognostic Factors for ASCT
Recommendation Grade of
Recommendation
Highest Level
of Evidence
References
Which factors at relapse
predict poor outcomes?
Anemia (hemoglobin < 10 g/dL)
Stage (III/IV)
Early relapse (<12 mo)
Systemic symptoms (B Sx)
Extranodal sites
Bulky disease at diagnosis
B 2þþ [20-22,24,25,31,40,41,59,61,62,
64,81,88,134-142]
Which pre-ASCT factors
predict better outcomes?
Chemosensitivity
CR or PR before transplant
Number of salvage regimens 2
C 2þ [20,22,24,29,32,57,64,66,138,
141,143-149]
What is the role of
FDG-PET imaging?
Negative PET before transplant is
associated with improved outcome
B 2þþ [51,69,81-87]
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[20,22,24,29,32,57,64,66,137,138,141,143-149]. For example,
in a study of 141 patients, the presence of chemoresistant
diseasewas independently associatedwith poor PFS (relative
risk, 2.9; 95% CI, 1.7 to 5.0) [141]. With a few exceptions
[20,22,23], similar ﬁndings have been observed in other se-
ries, including registry data [57,145].
Role of Functional Imaging
The use of pre-ASCT functional imaging has become
routine in patients with HL. Although historical data also
include gallium scans, FDG-PET is now considered the stan-
dard [51,69,81-87]. As noted above, in the study by Mosko-
witz et al. [51] that used sequential nonecross-resistant
regimens, a negative PET after salvage chemotherapy was
associated with an EFS rate > 80% compared with 26% in
patients with a positive PET pre-ASCT, highlighting the sig-
niﬁcance of a pre-ASCT negative PET scan. We recommend
the use of the Deauville scoring systemwhen reporting PET/
computed tomography results [150]. The system uses a 5-
point scale, with scans scored according to uptake in sites
initially involved by lymphoma as (1) no uptake, (2) uptake
equal to the mediastinum blood pool, (3) uptake equal to the
liver, (4) moderately increased uptake greater than the liver,
or (5) markedly increased uptake greater than the liver and/
or new lesions. A score of 1 to 3 is regarded as negative and 4
or 5 as positive.
Indications for Allo-HCT
Table 6 displays the indications for allo-HCT.
Role of Allo-HCT
Although relatively limited data assess the best approach
for patients who relapse after an ASCT, the available data
support the beneﬁt of allo-HCT versus standard therapy
[89,91,92,94,151]. In a multivariate analysis of 185 patientsTable 6
Allo-HCT in Patients with HL
Recommendation Grad
Reco
Should allo-HCT be used instead of conventional
therapy for patients who relapse after ASCT?
Yes B
What is the recommended regimen intensity? RIC B
Is there a preferred donor source? No A
When should DLI be given? Progressive disease/
relapsed
Incomplete donor
chimerism
B
D
What is the role of comorbidities in outcomes? Paucity of data dwho relapsed after ASCT performed by the Gruppo Italiano
Trapianto di Midollo Osseo, the 2 factors associated with
signiﬁcantly improved OS and PFS were having a donor and
relapse beyond 12 months after ASCT [92]. Patients from this
analysis were combinedwith European Society for Blood and
Marrow Transplantation (EBMT) data to analyze prognostic
factors in 511 patients who relapsed after ASCT [151].
Twenty-nine percent of patients underwent allo-HCT. In this
larger dataset, the factors that predicted OS were early
relapse (<6 months), stage IV, bulky disease, poor perfor-
mance status, and age  50 years at relapse. The 5-year OS
rate was 62% in patients with no risk factors compared with
37% and 12% for those having 1 and 2 factors, respectively.
Some patients with limited disease not previously irradiated
may beneﬁt from IFRT [90,93,94]. Although there are
currently limited data on the long-term beneﬁt of brentux-
imab vedotin salvage in the absence of allo-HCT [153], its use
before allo-HCT appears to be associated with improved PFS
compared with historical data [154].
Regimen intensity for allo-HCT
Early studies of allo-HCT in patients with HL reported in
the 1990s to 2000s demonstrated low OS due to high TRM,
likely resulting from the use of myeloablative conditioning
(MAC) in heavily pretreated patients (Supplemental Table 5)
[99,144,155]. In a retrospective comparison of MAC and
reduced-intensity conditioning (RIC) performed by the
EBMT, recipients of RIC had signiﬁcantly decreased non-
relapse mortality (hazard ratio, 2.85; 95% CI, 1.62 to 5.02; P <
.001) and improved OS (hazard ratio, 2.05; 95% CI, 1.27 to
3.29; P ¼ .04) compared with those who received MAC. The
improved OS in RIC was seen despite an increased risk of
relapse or progression. Furthermore, this study supported
the role of a graft-versus-lymphoma effect, with a signiﬁ-
cantly decreased incidence of relapse and a trend for a better
PFS associated with the development of chronic graft-e of
mmendation
Highest Level
of Evidence
References
2þþ [89-94,151]
2þþ [91,95-110,112]
1þ [96,100-102,104,105,111-113]
2þþ
3
[89,91,95-98,102,104,105,109,114,152]
[104,115]
d [104,105]
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PFS and OS rates of 30% and 56% at 1 year and 20% and 37% at
2 years, respectively, in HL patients after RIC HCT from un-
related donors [103]. These results are consistent with those
of other prospective and retrospective studies in which pa-
tients with HL were transplanted with RIC or nonablative
cytoreduction, with slightly better outcomes reported in
single-institution or multicenter studies [89,95-97,100-
102,104,107-110,114]. As a result, the preferred conditioning
intensity in adult patients with relapsed/refractory HL is RIC,
which results in acceptable TRM including in patients who
have had a prior ASCT. One of the commonly used regimens
in patients with HL is ﬂudarabine and melphalan
[96,97,102,107]. This regimen is also combined with alem-
tuzumab in some centers [95,115].
Pediatric studies of allo-HCT
In an EBMT study of pediatric patients, the TRM was
similar for RIC and MAC regimens [105]. However, RIC was
associated with higher risk of relapse compared with MAC,
most apparent beginning 9 months post-HCT (P ¼ .01).
Although PFS was lower in patients after RIC from 9 months
onward (P¼ .02), no difference was observed in OS. Despite a
potential higher risk of relapse, RIC has also become themost
commonly used regimen in pediatric patients.
Selection of donor source
Regarding preferred donor source, with the exception of a
study that showed worse outcomes in cord blood recipients
[112], no differences have been observed in analyses incor-
porating donor source [102,104]. It should be noted that only
9% of patients received cord blood in that study, and a recent
systematic review concluded that all donor sources,
including related, unrelated, and haploidentical donors and
cord blood, were a reasonable consideration for allo-HCT in
patients with HL [113]. Therefore, standard recommenda-
tions for donor selection for allo-HCT should be followed.
Role of donor lymphocyte infusions
A main beneﬁt of an allo-HCT is the graft-versus-
lymphoma effect [99]. The graft-versus-lymphoma effect
after donor lymphocyte infusion (DLI) has been documented
in a number of studies [89,91,95-98,102,104,105,109,115,152].
Peggs et al. [95] reported an ORR to DLI of 56% (CR ¼ 8, PR ¼
1) for persistent disease or progression in 16 patients after
allo-HCT. These ﬁndings were conﬁrmed in the UK Cooper-
ative Group study that reported an ORR of 79% (CR¼ 14, PR¼
5) for DLI in 24 patients who relapsed [115]. Both studies
incorporated alemtuzumab in the conditioning regimenwith
resultant in vivo T cell depletion and increased host chime-
rism, for which patients also received DLIs. The data on DLI
for incomplete donor chimerism is primarily derived from
these studies that include alemtuzumab, and its extension to
other conditioning regimens remains to be determined.Table 7
Autologous Stem Cell Transplant versus Allo-HCT
Recommend
Should allo-HCT be performed instead of ASCT as ﬁrst SCT? No
Should allo-HCT be performed instead of ASCT as
second SCT in most patients?
Yes
Should second ASCT be considered for
patients who relapse after ASCT?
Not within 1
Is there a role for tandem ASCT-allo-HCT? NoSimilar to other indications in allo-HCT, the best responses to
DLI were often associated with additional cytotoxic therapy
before DLI [102,104,109,152].
Salvage before allo-HCT
As noted above, brentuximab vedotin is indicated in pa-
tients who relapse after an ASCT or who fail to achieve a
remission after second-line therapy [122]. Also as noted
above, the use of brentuximab vedotin before allo-HCT ap-
pears to be associated with improved PFS compared with
historical data [154]. Beyond brentuximab vedotin, there is
no standard salvage regimen recommended before allo-HCT
for HL, and treatment selection depends on the patient’s
prior therapy and comorbidities. For further details on this
topic, readers are referred to a recent review of salvage
regimens in patients with HL relapsing after ASCT [156]. This
is a patient population for whom it is also reasonable to
consider investigational therapies.
Patients with comorbidities
Similar to ASCT, there are little data on comorbidities in
outcomes after allo-HCT in both pediatric and adult pop-
ulations. In the pediatric study by Claviez et al. [105], poor
performance status at HCT was associated with signiﬁcantly
increased risk of disease recurrence in univariate and
multivariate analyses. Poor performance status was also
identiﬁed as a risk factor for nonrelapse mortality in the
EBMT study [104].
Are There Indications for Allo-HCT Selection over ASCT?
ASCT versus allo-HCT as ﬁrst-line transplant
The studies that compare ASCT with allo-HCT as ﬁrst-line
transplant are older series that include MAC and do not
reﬂect current practice, which favors ASCT because the
additional risks of graft-versus-host disease in the allogeneic
setting are not generally considered to be warranted
[144,155,157] (Table 7). Up-front RIC allo-HCT has been re-
ported in subsets of patients as part of larger studies and
typically has been reserved for patients with poor prognostic
features [102,109]. Currently, insufﬁcient data support the
role of allo-HCT as ﬁrst-line transplant in patients with HL,
with the exception of patients who have another indication
for allo-HCT, such as concomitant diagnosis of myelodys-
plastic syndrome, for example. This is an area that requires
further investigation in patients with poor prognostic factors
indicating that ASCT is unlikely to be of beneﬁt.
Second ASCT versus allo-HCT
Similarly, limited data compare the beneﬁt of a second
ASCT versus an allo-HCT in patients who relapse after ASCT
[116,158]. For patients who relapse within the ﬁrst year after
ASCT, outcomes with a second ASCT have been very poor
[92,116]. Based on the available data, the current practice is to
offer most patients an allo-HCT over a second ASCT. Becauseation Grade of
Recommendation
Highest Level
of Evidence
References
C 2þ [144,155,157]
C 2þ [90,116]
year C 2þ [92,116,158]
D 4 [91]
Table 8
Prognostic Factors for Allo-HCT
Recommendation Grade of
Recommendation
Highest Level
of Evidence
References
Are there useful prognostic factors before allo-HCT? Yes B 2þþ [92,103,105,112,159,160]
Is there a role for PET imaging? To be determined C 2þ [161]
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nors, this option should be available to most patients who
otherwise meet criteria for allo-HCT.
Tandem autologous-allogeneic HCT
Tandem autologous-allogeneic HCT has been proposed
for patients with poor-risk HL at high risk for relapse after
ASCT [91]. Similar to other diseases, currently very limited
data support this approach.Prognostic Factors for Allo-HCT
Although there are less data regarding prognostic factors
before allo-HCT, the data are consistent with factors that are
predictive of outcomes for ASCT (Table 8). The data are
derived either from studies that have evaluated relapse after
ASCT or studies of allo-HCT [92,103,105,112,159]. In the
Gruppo Italiano Trapianto di Midollo Osseo study described
above, status at HCT (PR versus CR and PD/stable disease
versus CR) was associated with signiﬁcantly worse OS and
PFS [92]. This ﬁnding was conﬁrmed in the EBMT study and a
recent Societe Francaise de Greffe de Moelle study [104,112].
PFS and OS were both associated with performance status
and disease status at transplant in the EBMT study [104].
Patients with neither risk factor had a 3-year PFS and OS
rates of 42% and 56%, respectively, compared with 8% and
25% for patients with one or more risk factors. In contrast, in
the CIBMTR study, the presence of extranodal disease and a
Karnofsky performance scale score< 90 were signiﬁcant risk
factors for TRM, PFS, and OS, whereas chemosensitivity at
transplantationwas not [103]. In another study that included
40 patients with HL who had active or progressive disease at
the time of HCT, the 3-year OS and PFS rates after allo-HCT
were 49%  8% and 17%  6%, respectively [160].
In a study of FDG-PET performed before allo-HCT in pa-
tients with HL (n ¼ 46) and non-HL (n ¼ 34), patients with
positive FDG-PET scans had a 3-year risk of relapse of 59%
(95% CI, 41% to 86%) compared with 27% (95% CI, 13% to 55%;
P < .066) in those with a negative scan [161]. Of note, the
crude cumulative incidence of disease recurrence in patients
with HL was 59% (95% CI, 41% to 86%) in those with a positive
FDG-PET scan and 27% (95% CI, 13% to 55%; P ¼ .066) in those
with a negative scan. A recent study also identiﬁed serum
thymus and activation-regulated chemokine, which is pro-
duced by Reed-Sternberg cells, as a potential biomarker forTable 9
Survivorship after ASCT or allo-HCT
Complication
What is the long-term toxicity of ASCT? Second malignancy
Organ impairment
Reduced quality of life
What is the long-term toxicity of allo-HCT? Chronic graft-versus-host diseas
organ impairment, reduced
quality of life
Are there guidelines for follow-up? Yespoor prognosis [162]. In patients who relapsed after allo-SCT,
thymus and activation-regulated chemokine level increased
progressively and preceded evidence of PET-positive disease.
Further research is warranted on the prognostic signiﬁcance
of PET imaging before allo-HCT in HL.Survivorship in HL Patients after ASCT and Allo-HCT
The main complications observed after ASCT in patients
with HL are similar to those seen in other hematologic ma-
lignancies (Table 9) and include secondary malignancy, or-
gan impairment, and reduced quality of life
[25,29,82,145,146,163-170]. Similarly, the complications
seen in recipients of allografts are consistent with compli-
cations of allo-HCT in general. In the report from the Bone
Marrow Transplantation Survivor Study, the morbidity
burden was assessed in 324 (HL ¼ 26) 10þ year survivors of
autologous and allogeneic HCT [170]. The 15-year cumulative
incidence of severe, life-threatening, or fatal conditions was
41%, and HCT survivors were 5.7 times as likely to develop
severe or life-threatening conditions and 2.7 times as likely
to report somatic distress compared with siblings. ASCT re-
cipients had a similar incidence of chronic health conditions
compared with allo-HCT recipients. These are signiﬁcant
limitations considering the young median age of patients
undergoing HCT for HL. Readers are referred to published
recommended guidelines for the follow-up of patients after
autologous and allogeneic HCT [171,172].AREAS OF NEEDED RESEARCH AND ONGOING RESEARCH
Although there are established data supporting the role
of HCT in patients with advanced HL, several areas would
beneﬁt from further study. In particular, there is a paucity
of data regarding the outcomes after both autologous and
allogeneic HCT in older patients or patients with comor-
bidities. In addition, prospective studies investigating the
role of prognostic factors would also be helpful in
improving patient selection for HCT as well as the use of
risk-adapted therapy to reduce the risk of relapse while
minimizing toxicity. These studies may also identify pa-
tients who would beneﬁt from allo-HCT over ASCT. Pa-
tients who undergo either autologous or allogeneic HCT
still carry a signiﬁcant risk of relapse, and further work is
required to develop strategies to reduce this risk.Grade of
Recommendation
Highest Level
of Evidence
References
B
B
B
2þþ
2þþ
2þþ
[25,29,82,145,163-166]
[25,146,167,168]
[25,146,165-167,169,170]
e, B 2þþ [170]
N/A N/A [171,172]
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that most data on which these recommendations are based
precedes the approval of newer agents that are being
routinely incorporated into treatment algorithms for patients
with HL. In particular, recent or ongoing studies have exam-
ined the role of brentuximab vedotin in several settings,
including up-front treatment (NCT01712490), salvage treat-
ment (NCT01508312, NCT01393717, NCT01874054) [123-
125], and post-transplant maintenance [80]. Results of these
studies should further inform the role of this active agent in
the management of patients with HL. In addition to bren-
tuximab vedotin, other drugs shown to have activity after
ASCT relapse or being investigated in that setting include
bendamustine [173,174], the mTOR inhibitor everolimus
[175], and,more recently, immune checkpoint blockadedrugs
such as the anti-PD-1 antibody nivolumab [176].
CONCLUSIONS
Both ASCT and allo-HCT offer a survival beneﬁt in
selected patients with advanced or relapsed HL and are
currently part of standard clinical care. Patients who
relapse after frontline therapy are offered salvage second-
line chemotherapy regimens followed by high-dose ther-
apy and ASCT. In randomized studies, ASCT offered as
salvage therapy improved EFS and PFS compared with
nontransplant approaches, although these studies were
not powered to show a beneﬁt in OS. In patients who
relapse after ASCT, allo-HCT is considered the standard
approach for patients with a donor. The main adverse
prognostic factors identiﬁed in both transplant settings
include short remission duration, either to frontline ther-
apy or ASCT. The main favorable prognostic factors are
presence of chemosensitive disease and negative pre-HCT
FDG-PET imaging results. Relapse remains a signiﬁcant
cause of failure after both transplant approaches, and
strategies to decrease the risk of relapse through the use of
post-transplant maintenance and/or DLI in the case of allo-
HCT warrant further investigation.
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